Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179812 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL2179807 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL4983780 | 0.88 | ADRB2 (0.55) | ADRB2ADRB1ADRB3ALDH1A1MAPT | |
| SCHEMBL31379961 | 0.87 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL31379970 | 0.87 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL31379964 | 0.87 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL31379971 | 0.87 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL14612799 | 0.86 | ADRB2 (0.68) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL31379979 | 0.84 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CA1CA2 | |
| SCHEMBL31379972 | 0.84 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2010107384-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1971598-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007061670-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | ADRB2 863/4885ADRB1 462/4885ADRB3 576/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | ADRB2 863/4885ADRB1 462/4885ADRB3 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.